Virtus ETF Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,279
| Closed | -$65.4K | – | 370 |
|
|
2024
Q4 | $65.4K | Sell |
1,279
-683
| -35% | -$34.9K | 0.03% | 415 |
|
|
2024
Q3 | $100K | Buy |
1,962
+31
| +2% | +$1.58K | 0.05% | 375 |
|
|
2024
Q2 | $86.5K | Sell |
1,931
-548
| -22% | -$24.5K | 0.04% | 377 |
|
|
2024
Q1 | $116K | Sell |
2,479
-175
| -7% | -$8.19K | 0.06% | 349 |
|
|
2023
Q4 | $94.4K | Sell |
2,654
-2,195
| -45% | -$78.1K | 0.06% | 387 |
|
|
2023
Q3 | $144K | Sell |
4,849
-484
| -9% | -$14.4K | 0.09% | 313 |
|
|
2023
Q2 | $96.1K | Sell |
5,333
-882
| -14% | -$15.9K | 0.06% | 404 |
|
|
2023
Q1 | $99.8K | Sell |
6,215
-2,383
| -28% | -$38.3K | 0.05% | 340 |
|
|
2022
Q4 | $157K | Buy |
8,598
+2,370
| +38% | +$43.4K | 0.08% | 332 |
|
|
2022
Q3 | $122K | Buy |
6,228
+48
| +0.8% | +$940 | 0.05% | 395 |
|
|
2022
Q2 | $115K | Sell |
6,180
-166
| -3% | -$3.09K | 0.04% | 396 |
|
|
2022
Q1 | $139K | Sell |
6,346
-380
| -6% | -$8.32K | 0.06% | 239 |
|
|
2021
Q4 | $191K | Sell |
6,726
-4,499
| -40% | -$128K | 0.07% | 225 |
|
|
2021
Q3 | $236K | Sell |
11,225
-585
| -5% | -$12.3K | 0.1% | 226 |
|
|
2021
Q2 | $223K | Sell |
11,810
-10,072
| -46% | -$190K | 0.09% | 266 |
|
|
2021
Q1 | $334K | Buy |
21,882
+395
| +2% | +$6.03K | 0.14% | 218 |
|
|
2020
Q4 | $303K | Buy |
21,487
+2,116
| +11% | +$29.8K | 0.13% | 205 |
|
|
2020
Q3 | $304K | Sell |
19,371
-2,655
| -12% | -$41.7K | 0.16% | 218 |
|
|
2020
Q2 | $386K | Buy |
+22,026
| New | +$386K | 0.18% | 212 |
|
|
2019
Q2 | – | Sell |
-7,934
| Closed | -$181K | – | 438 |
|
|
2019
Q1 | $181K | Sell |
7,934
-1,100
| -12% | -$25.1K | 0.39% | 92 |
|
|
2018
Q4 | $271K | Buy |
+9,034
| New | +$271K | 0.05% | 143 |
|